Teleflex/$TFX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Teleflex
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
- Ticker
- $TFX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 15,500
- Headquarters
- Wayne, United States
- Website
- www.teleflex.com
Teleflex Metrics
BasicAdvanced
$6B
-
-$23.41
0.81
$1.36
0.96%
Price and volume
Market cap
$6B
Beta
0.81
52-week high
$145.00
52-week low
$100.18
Average daily volume
788K
Dividend rate
$1.36
Financial strength
Current ratio
2.604
Quick ratio
0.923
Long term debt to equity
0.959
Total debt to equity
1.011
Interest coverage (TTM)
1.74%
Profitability
EBITDA (TTM)
403.903
Gross margin (TTM)
55.05%
Net profit margin (TTM)
-45.76%
Operating margin (TTM)
9.54%
Effective tax rate (TTM)
60.58%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
1.75%
Return on equity (TTM)
-0.70%
Valuation
Price to revenue (TTM)
2.764
Price to book
2.06
Price to tangible book (TTM)
-7.16
Price to free cash flow (TTM)
19.051
Free cash flow yield (TTM)
5.25%
Free cash flow per share (TTM)
7.422
Dividend yield (TTM)
0.96%
Forward dividend yield
0.96%
Growth
Revenue change (TTM)
110.94%
Earnings per share change (TTM)
-660.80%
3-year revenue growth (CAGR)
-8.04%
10-year revenue growth (CAGR)
2.18%
3-year earnings per share growth (CAGR)
44.27%
10-year earnings per share growth (CAGR)
15.31%
What the Analysts think about Teleflex
Analyst ratings (Buy, Hold, Sell) for Teleflex stock.
Analyst projections of the future price of Teleflex stock.
Bulls say / Bears say
Vascular and Surgical provided solid underlying momentum in Q2: revenue rose 8.0% and 9.2%, respectively, helping offset weakness in Interventional. (The Motley Fool)
EZPLAZ became the first freeze-dried plasma licensed by the FDA, while Freesolve advanced through early clinical milestones, including ahead-of-schedule BIOMAG-II enrolment. These products offer growth potential, though Freesolve remains at an early stage. (Teleflex)
Teleflex cut its 2026 pro forma adjusted constant-currency revenue growth outlook to 3.5%–4.5% from 4.5%–5.5%, citing a longer-than-expected integration of the acquired Vascular Intervention business; Interventional revenue fell 1.0% on that basis in Q2. (Teleflex, The Motley Fool)
Profitability is under pressure: Q2 adjusted gross margin fell 280 basis points and adjusted operating margin fell 520 basis points year on year, with tariffs and the acquired business's lower-margin mix among the factors cited. (The Motley Fool)
The Acute Care and Interventional Urology sale was still awaiting FTC review, with completion expected in Q4; separation costs reached $59.2 million in the first half, leaving execution and transition costs as near-term risks. (The Motley Fool, Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Teleflex Financial Performance
Revenues and expenses
Teleflex Earnings Performance
Company profitability
Upcoming events
No upcoming events
Teleflex News
AllArticlesVideos
Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
Business Wire1 week ago
Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
Business Wire3 weeks ago
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
Business Wire1 month ago
Funds containing Teleflex
AllUSDEURGBP
Fund name | Fund size | $TFX weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.33% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.33% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.15% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.15% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.